Monday, 31 August 2026European Markets

MKB Nedsense Stock Is 10% Up So Far Today

Loading stream...

(VIANEWS) - Shares of MKB Nedsense (AEX-Index: NEDSE.AS) jumped by a staggering 10.91% to €0.12 at 14:08 EST on Monday, after three sequential sessions in a row of losses. AEX-Index is falling 0.13% to €755.65, after five successive sessions in a row of losses. This seems, so far, a somewhat bearish trend exchanging session today.

MKB Nedsense's last close was €0.11, 28.1% below its 52-week high of €0.15.

About MKB Nedsense

MKB Nedsense N.V. engages in the finance and lending of money to natural persons and legal entities. It also provides guarantees and/or other securities towards third parties for its obligations and/or for obligations for companies in the investment portfolio. The company was formerly known as Nedsense Enterprises N.V. MKB Nedsense N.V. was founded in 1999 and is based in Bussum, the Netherlands.

Moving Average

MKB Nedsense's value is higher than its 50-day moving average of €0.12 and under its 200-day moving average of €0.13.

Yearly Top and Bottom Value

MKB Nedsense's stock is valued at €0.12 at 14:08 EST, way below its 52-week high of €0.15 and way above its 52-week low of €0.09.

Volume

Today's last reported volume for MKB Nedsense is 4748 which is 84.96% below its average volume of 31585.

More news about MKB Nedsense (NEDSE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com